PP1420 in Pancreatic Diabetes
Research type
Research Study
Full title
A randomised placebo-controlled study of the pancreatic polypeptide analogue PP 1420 in patients with Pancreatogenic Diabetes (a pilot study)
IRAS ID
248278
Contact name
Bernard Khoo
Contact email
Sponsor organisation
University College London
ISRCTN Number
ISRCTN62158841
Clinicaltrials.gov Identifier
Health research, Z6364106/2019/01/127
Duration of Study in the UK
1 years, 1 months, 30 days
Research summary
The pancreas is the organ in the human body that secretes the hormone insulin which controls blood sugar levels. If the pancreas is damaged, or if the pancreas is removed during surgery, patients develop a type of diabetes called Pancreatogenic Diabetes (PD for short). Patients with PD, unlike the more common types of diabetes, suffer from much more variable blood sugar levels with very high followed by extremely low blood sugar levels which can kill. The reason for such swinging blood sugar levels is due to the lack of a pancreatic hormone called pancreatic polypeptide (PP), which reduces the liver’s sensitivity to the action of insulin. Replacing PP in patients with PD improves the sensitivity of the liver to insulin, reducing the amount of insulin they need to control their diabetes and reducing the likelihood of low blood sugar. We have devised a new ‘analogue’ of PP, which can be injected under the skin, and which lasts for a longer time than PP itself. In this project, we are going to study patients with PD where we will test the PP analogue PP 1420 for its ability to improve liver insulin sensitivity. If this is shown to occur, then PP 1420 can be quickly developed as a treatment for patients with PD to help reduce high blood sugar levels, and to help prevent low blood sugar levels.
REC name
London - City & East Research Ethics Committee
REC reference
19/LO/0315
Date of REC Opinion
29 Mar 2019
REC opinion
Further Information Favourable Opinion